Bessemer Group
NRIX icon

Bessemer Group’s Nurix Therapeutics NRIX Stock Holding History

Bessemer Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.74M Hold
306,003
– – 0.01% 495
2025
Q4 		$5.8M Hold
306,003
– – 0.01% 391
2025
Q3 		$2.83M Hold
306,003
– – ﹤0.01% 441
2025
Q2 		$3.48M Hold
306,003
– – 0.01% 399
2025
Q1 		$3.64M Hold
306,003
– – 0.01% 392
2024
Q4 		$5.76M Sell
306,003
-50
-0% -$1.15K 0.01% 385
2024
Q3 		$6.88M Buy
306,053
+50
+0% +$1.13K 0.01% 359
2024
Q2 		$6.39M Sell
306,003
-51,284
-14% -$799K 0.01% 341
2024
Q1 		$5.25M Hold
357,287
– – 0.01% 380
2023
Q4 		$3.69M Hold
357,287
– – 0.01% 403
2023
Q3 		$2.81M Hold
357,287
– – 0.01% 421
2023
Q2 		$3.57M Hold
357,287
– – 0.01% 397
2023
Q1 		$3.17M Hold
357,287
– – 0.01% 393
2022
Q4 		$3.92M Hold
357,287
– – 0.01% 363
2022
Q3 		$4.66M Buy
357,287
+52,274
+17% +$827K 0.01% 330
2022
Q2 		$3.86M Hold
305,013
– – 0.01% 337
2022
Q1 		$4.27M Buy
305,013
+251
+0.1% +$4.46K 0.01% 263
2021
Q4 		$8.82M Sell
304,762
-23,857
-7% -$723K 0.02% 214
2021
Q3 		$9.85M Buy
328,619
+23,857
+8% +$736K 0.02% 220
2021
Q2 		$8.09M Hold
304,762
– – 0.02% 230
2021
Q1 		$9.47M Buy
+304,762
New +$11.5M 0.02% 230

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bessemer Group's NRIX Position: Q1 2026 in Review

Bessemer Group held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 306,003 shares worth $4.74M. The position accounts for 0.01% of the portfolio, ranked #495.

Bessemer Group first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $9.85M in Q3 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Bessemer Group held 306,003 shares of Nurix Therapeutics worth $4.74M as of Q1 2026.
  • Bessemer Group left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #495 holding.
  • Bessemer Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Bessemer Group's Nurix Therapeutics position peaked at $9.85M in Q3 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.